Hemoglobin interference in laboratory analyses due to hemolysis has been well characterized [1] [2] [3] . Laboratory scientists are becoming sensitized to an additional iatrogenic cause of interference from hemoglobin. Stabilized hemoglobin-based oxygen carriers (HBOCs) have potential applications in trauma and emergency surgery, perioperative hemodilution, cardiopulmonary bypass, and hematopoiesis [4] . Several of these products are in late clinical trials and are nearing marketing approvals. As a result, there has been increasing interest in the effects of these HBOCs on routine laboratory assays by clinical chemists and diagnostic reagent manufacturers. This paper presents the results of a study that examined the effects of an HBOC, o-raffinose cross-linked hemoglobin (Hemolink TM ) on selected routine assays on the Hitachi 717 with reagents from Boehringer Mannheim Corp. (BMC). Hemolink is prepared from hemoglobin purified from outdated human red blood cells previously tested and released for use in transfusion. The purified hemoglobin reacts with o-raffinose, a polyaldehyde obtained through oxidation of raffinose [5, 6] . As a result, two hemoglobin ␣␤ dimers are covalently cross-linked between amino groups within the 2,3-diphosphoglycerate binding pocket to form stable hemoglobin tetramers (64 kDa). In addition, o-raffinose reacts with surface amino groups to form intermolecular linkages producing stable hemoglobin polymers (128 -600 kDa). The final Hemolink preparation contains ϳ40% of the hemoglobin tetramer and ϳ60% of the hemoglobin polymers.
To study the effects of Hemolink on the measurement of routine analytes, three normal plasma pools and one plasma pool with increased analyte concentrations were prepared and tested with each of two lots of Hemolink to determine (a) whether there were pool-to-pool or (b) lot-to-lot differences in the interferences observed, and (c) whether the interference was dependent on analyte concentration. All samples were collected in compliance with institutional ethical standards. Samples were diluted 4:1 (by vol) with Hemolink and (or) lactated Ringer's injection USP (excipient for Hemolink) to obtain final Hemolink concentrations of 0.0 (control), 1.25, 2.5, 5.0, 7.5, 10, 15, and 20 g/L, measured as total hemoglobin.
Methods tested on the Hitachi 717 with BMC reagents included those for sodium, potassium, chloride, urea (urease), creatinine (kinetic Jaffe), total bilirubin (2,5dichlorophenyldiazonium tetrafluoroborate), albumin (bromcresol green), total protein (biuret), calcium (ocresolphthalein complexone), phosphorus (molybdate), glucose (hexokinase, glucose-6-phosphate dehydrogenase), alkaline phosphatase (ALP; p-nitrophenyl phosphate, AMP buffer), alanine aminotransferase (ALT; IFCC), aspartate aminotransferase (AST; IFCC), ␥-glutamyltransferase (GGT; glutamyl-3-carboxy-4-nitroanilide, glycylglycine), creatine kinase (CK; NAC-activated), lactate dehydrogenase (LDH; lactate, NAD ϩ ), and iron (ferrozine). As little as 0.5 g/L added HBOC increased the measured albumin concentration and decreased phenytoin beyond acceptable values on the Vitros analyzer but had no effect on the Dimension system. Calcium results were not affected on the DAX, CX-3, and Vitros analyzers.
Interference was calculated in terms of the absolute and relative error. Absolute error is defined as A I Ϫ A 0 , where A I is the analyte concentration in the sample containing the interferent and A 0 is the analyte concentration in the control sample containing no interferent [7] . Relative error is the ratio of these values and is calculated as A I /A 0 [7] . The interference of Hemolink was considered significant when the relative error exceeded a limit of 3 ϫ CV of each method.
No interference was observed for Na, K, Cl, urea, glucose, total protein, CK, AST, calcium, and phosphorus up to 20 g/L Hemolink. Clinically significant interference was observed for albumin and ALT at Hemolink concentrations Ͼ5.0 g/L; for creatinine, total bilirubin, LDH, and GGT at Hemolink concentrations Ͼ1.25 g/L; and for ALP and iron at all Hemolink concentrations tested. There were no significant differences in the absolute or relative error between the normal and abnormal sample pools tested and no significant differences between the two lots of Hemolink tested. In addition, the interference was directly proportional to the Hemolink concentration in the sample and was independent of the analyte concentration in the range of values tested, with the exception of bilirubin. The error in the total bilirubin measurement varied with both the Hemolink and bilirubin concentration in the sample, similar to results reported previously for the interference of hemolysis with the BMC bilirubin method on the Hitachi 717 [7] . For all analytes having linear interference from Hemolink, the absolute error per g/L Hemolink and regression parameters from analysis of the absolute error vs Hemolink concentration are summarized in Table 1 . The error per g/L Hemolink differs significantly from the reported effect of hemolysis on similar assays because of the presence of intracellular contaminants from erythrocytes (e.g., LDH, AST, K, and adenylate kinase) [7] .
For those analytes showing significant interference from Hemolink, several variables were considered before reporting the results. First, the hemoglobin concentration of the sample was considered. Results for albumin, ALT, creatinine, total bilirubin, LDH, and GGT were within acceptable limits (Ϯ3 ϫ CV) in the presence of low amounts of Hemolink, as described above. The intraindividual biological variability of each analyte was also considered. If the interference from Hemolink fell within the combined analytical and biological variability [8 -10] , Hemolink was not considered to interfere with clinical interpretation of the results. And finally, in conjunction with medical personnel, the interference was considered along with the magnitude and time course of changes in each affected analyte associated with disease states. If the interference by Hemolink was not considered to obscure a clinically significant change in analyte concentration, the results were considered reportable. For example, at a plasma concentration of 20 g/L Hemolink, reported ALT values would be underestimated by 14 U/L. This interference could not be distinguished from the biological variability of ALT [8] and would not mask increases associated with hepatic disorders such as obstructive jaundice [2-10 times the upper limit of normal (ULN)] or viral hepatitis (Ͼ4 ϫ ULN) [11, 12] . Therefore, ALT values were considered reportable in the presence of Hemolink. In contrast, at 20 g/L plasma Hemolink, ALP values would be underestimated by ϳ120 U/L. This interference could mask increases in ALP after hepatitis or mild obstructive jaundice (2-5ϫ ULN) [13, 14] . Thus ALP values were not considered reportable in the presence of Hemolink.
Although the Hemolink concentration of the sample and the slope of the linear regression line can be used to predict the error in a given analyte measurement, correction factors should be used with caution. The laboratory should confirm that interference is caused only by the HBOC and not by hemolysis, since the correction factors for interference from hemolysis will differ from those of HBOCs because of the contribution of intracellular components of red cells (e.g., K, AST, and LDH) [1, 7] . In addition, whether correction factors can be transferred between analyzers, reagents, or different types of HBOCs is not currently known.
In conclusion, BMC methods on the Hitachi 717 were acceptable for the clinical evaluation of electrolyte and calcium balance, urea, glucose, total protein, CK, and AST for plasma Hemolink concentrations up to 20 g/L. However, creatinine, LDH, GGT, total bilirubin, albumin, ALT, ALP, and iron had significant interference; thus, clinical- 
